Biotech News
C4 Therapeutics to Participate in Upcoming March Conferences
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.
TD Cowen 46 th Annual Healthcare Conference: Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.
Barclays 28 th Annual Global Healthcare Conference: Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami, Florida.
The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com . The archived replays of the webcasts will be available for approximately 90 days following the events.
About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com .
Contacts: Investors: Courtney Solberg Associate Director, Investor Relations [email protected]
Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy [email protected]
